Abstract
In the late 1980s, reports emerged describing experimental antibacterial quinolones having significant potency against eukaryotic Type II topoisomerases (topo II) and showing cytotoxic activity against tumor cell lines. As a result, several pharmaceutical companies initiated quinolone anticancer programs to explore the potential of this class in comparison to conventional human topo II inhibiting antitumor drugs such as doxorubicin and etoposide. In this review, we present a modern re-evaluation of the anticancer potential of the quinolone class in the context of today’s predominantly pathway-based (rather than cytotoxicity-based) oncology drug R&D environment. The quinolone eukaryotic SAR is comprehensively discussed, contrasted with the corresponding prokaryotic data, and merged with recent structural biology information which is now beginning to help explain the basis for that SAR. Quinolone topo II inhibitors appear to be much less susceptible to efflux-mediated resistance, a current limitation of therapy with conventional agents. Recent advances in the biological understanding of human topo II isoforms suggest that significant progress might now be made in overcoming two other treatment-limiting disadvantages of conventional topo II inhibitors, namely cardiotoxicity and drug-induced secondary leukemias. We propose that quinolone class topo II inhibitors could have a useful future therapeutic role due to the continued need for effective topo II drugs in many cancer treatment settings, and due to the recent biological and structural advances which can now provide, for the first time, specific guidance for the design of a new class of inhibitors potentially superior to existing agents.
Keywords: Quinolone, fluoroquinolone, topoisomerase, gyrase, topo II, topo IV, antitumor, anticancer, cytotoxic, antibacterial, selectivity, Paul Ehrlich, magic bullet, doxorubicin, etoposide, vosaroxin, quarfloxin, G quadruplex.
Current Medicinal Chemistry
Title:A “Double-Edged” Scaffold: Antitumor Power within the Antibacterial Quinolone
Volume: 23 Issue: 6
Author(s): Gregory S. Bisacchi and Michael R. Hale
Affiliation:
Keywords: Quinolone, fluoroquinolone, topoisomerase, gyrase, topo II, topo IV, antitumor, anticancer, cytotoxic, antibacterial, selectivity, Paul Ehrlich, magic bullet, doxorubicin, etoposide, vosaroxin, quarfloxin, G quadruplex.
Abstract: In the late 1980s, reports emerged describing experimental antibacterial quinolones having significant potency against eukaryotic Type II topoisomerases (topo II) and showing cytotoxic activity against tumor cell lines. As a result, several pharmaceutical companies initiated quinolone anticancer programs to explore the potential of this class in comparison to conventional human topo II inhibiting antitumor drugs such as doxorubicin and etoposide. In this review, we present a modern re-evaluation of the anticancer potential of the quinolone class in the context of today’s predominantly pathway-based (rather than cytotoxicity-based) oncology drug R&D environment. The quinolone eukaryotic SAR is comprehensively discussed, contrasted with the corresponding prokaryotic data, and merged with recent structural biology information which is now beginning to help explain the basis for that SAR. Quinolone topo II inhibitors appear to be much less susceptible to efflux-mediated resistance, a current limitation of therapy with conventional agents. Recent advances in the biological understanding of human topo II isoforms suggest that significant progress might now be made in overcoming two other treatment-limiting disadvantages of conventional topo II inhibitors, namely cardiotoxicity and drug-induced secondary leukemias. We propose that quinolone class topo II inhibitors could have a useful future therapeutic role due to the continued need for effective topo II drugs in many cancer treatment settings, and due to the recent biological and structural advances which can now provide, for the first time, specific guidance for the design of a new class of inhibitors potentially superior to existing agents.
Export Options
About this article
Cite this article as:
Bisacchi S. Gregory and Hale R. Michael, A “Double-Edged” Scaffold: Antitumor Power within the Antibacterial Quinolone, Current Medicinal Chemistry 2016; 23 (6) . https://dx.doi.org/10.2174/0929867323666151223095839
DOI https://dx.doi.org/10.2174/0929867323666151223095839 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer
Current Cancer Drug Targets Identification of Flavonoids as Potent Inhibitors Against MERS-CoV 3C-like Protease
Coronaviruses Rationally Designed Multi-Targeted Agents Against Neurodegenerative Diseases
Current Medicinal Chemistry Anticancer Drug Discovery from the Marine Environment
Recent Patents on Anti-Cancer Drug Discovery Hydrogen Commonly Applicable from Medicine to Agriculture: From Molecular Mechanisms to the Field
Current Pharmaceutical Design Small is Beautiful: What Can Nanotechnology Do for Personalized Medicine?
Current Pharmacogenomics and Personalized Medicine Nitrofurantoin Pulmonary Toxicity: Neglected Threat
Current Drug Safety Comparison of QSARs and Characterization of Structural Basis of Bioactivity Using Partial Order Theory and Formal Concept Analysis: A Case Study with Mutagenicity
Current Computer-Aided Drug Design A Perspective on Quantum Mechanics Calculations in ADMET Predictions
Current Topics in Medicinal Chemistry A Dual Mode Pulsed Electro-Magnetic Cell Stimulator Produces Acceleration of Myogenic Differentiation
Recent Patents on Biotechnology Triazole Nucleoside Derivatives Bearing Aryl Functionalities on the Nucleobases Show Antiviral and Anticancer Activity
Mini-Reviews in Medicinal Chemistry Role of Potential COVID-19 Immune System Associated Genes and the Potential Pathways Linkage with Type-2 Diabetes
Combinatorial Chemistry & High Throughput Screening Chalcones as Versatile Synthons for the Synthesis of 5- and 6-membered Nitrogen Heterocycles
Current Organic Chemistry Evaluation of the Antimicrobial Activity of Some 4H-Pyrano[3,2-h]- quinoline,7H-Pyrimido[4',5':6,5]pyrano[3,2-h]quinoline Derivatives
Letters in Drug Design & Discovery Prolonged Physiologic Doses of Corticosteroids for the Treatment of Severe Community Acquired Pneumonia
Current Respiratory Medicine Reviews ISIDA - Platform for Virtual Screening Based on Fragment and Pharmacophoric Descriptors
Current Computer-Aided Drug Design Withdrawal Notice: In Drug Repurposing Tactics against Covid-19
Current Psychopharmacology Discovery of Potential Inhibitors of the Receptor-binding Domain (RBD) of Pandemic Disease-causing SARS-CoV-2 Spike Glycoprotein from Triphala Through Molecular Docking
Current Chinese Chemistry Hsp90 Inhibition with Resorcylic Acid Lactones (RALs)
Current Topics in Medicinal Chemistry Anti-Inflammatory Iridoids of Botanical Origin
Current Medicinal Chemistry